Enter Note Done
Go to previous page in this tab
Event
  • Scientific Session
  • Bookmark Icon
  • Integrating New Data Streams into the Developmental Neurotoxicity In Vitro Battery
  • Schedule
    Notes
  • Stars at Night Ballroom B2‚ Convention Center
    Set Timezone


Chair: Christopher McPherson, NIEHS/DTT
Co-Chair: Sachana Magdalini, Organisation for Economic Co-operation and Development, France

Primary Endorser: Neurotoxicology Specialty Section


Endorser(s): Risk Assessment Specialty Section


Endorser(s): In Vitro and Alternative Methods Specialty Section


Exposure to chemicals can pose a significant threat to the developing nervous system, yet relatively few chemicals are evaluated for their potential to cause developmental neurotoxicity (DNT) using Organisation for Economic Cooperation and Development (OECD) Test Guidelines due to time, cost, and ethical constraints associated with rodent in vivo guideline studies. To address this testing gap, extensive international efforts have focused on the development and regulatory application of new approach methodologies (NAMs) for DNT hazard assessment. These efforts led to the creation of the Developmental Neurotoxicity in vitro battery (DNT IVB), which is composed of multiple human- and rodent based cell assays designed to capture key neurodevelopmental processes, including cell proliferation, migration, differentiation, neurite outgrowth, synaptogenesis, and neuronal network formation. This work culminated in the OECD Initial Recommendations on Evaluation of Data from the DNT IVB, published in 2023, which formalized a 17 assay battery and provided guidance for its interpretation within Integrated Approaches to Testing and Assessment (IATA). While the DNT IVB has demonstrated considerable value as a screening tool and through IATA case studies, uncertainties remain that must be addressed to support broader regulatory confidence and application, including optimal endpoint selection, the biological coverage of the battery, sensitivity to known developmental neurotoxicants, and the translation of in vitro activity concentrations to human relevant exposure contexts. As a first step, the OECD recently published the principles of quantitative in vitro to in vivo extrapolation (QIVIVE) applied to DNT-IVB. Developmental neurotoxicity is uniquely positioned to advance NAM based hazard assessment due to highly coordinated efforts by the OECD, U.S. Environmental Protection Agency, and European Food Safety Authority, and academic and governmental partners, and as such, the DNT IVB is best viewed as an evolving framework rather than a static tool. This session will highlight recent advances reflecting the continued evolution of the DNT IVB and its integration with complementary data streams, while also addressing ongoing challenges in practical implementation, including the added predictive value of multiple assays and their translational potential for human health. The four presentations will cover 1) international harmonization and regulatory considerations, 2) data-driven approaches to evaluating battery performance and optimizing assay integration, 3) incorporation of zebrafish developmental neurobehavioral assays to enhance biological coverage and mechanistic anchoring, and 4) application of in vitro-to-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modeling to contextualize DNT IVB results for human health risk assessment and chemical prioritization. Together, these presentations will provide a comprehensive overview of how integrated NAM strategies are advancing DNT hazard assessment, addressing key uncertainties, and moving the field toward more efficient, biologically informed, and risk-relevant decision making.
Session and Activity Type
Presentations